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SIGNIFICANCE STATEMENT
Autoimmune disease pathogenesis is driven by inflammation, induced partly by IgG autoantibody-containing immune complexes binding to Fc gamma receptors (Fc Rs). These receptors are widely considered to be valid therapeutic targets in the treatment of autoimmunity. FcgRIIIa is one of a family of highly homologous receptors for IgG antibodies; previous attempts at therapeutic blockade have resulted in off-target effects involving cells which express the almost identical protein FcgRIIIb. Here we report the identification of functionally specific protein-based inhibitors (Affimer proteins) of FcgRIIIa and the structural/functional basis of their selectivity. As molecular research tools FcgRIIIa-specific Affimer proteins provide the ability to block IgG interaction with a single receptor. Our findings suggest that highly selective protein-based blocking agents that may have therapeutic applications can be readily produced.
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Improved understanding of genetic, genomic and cellular processes underpinning human disease have led to the identification of a multitude of protein-protein interactions that represent potentially important therapeutic targets, frequently for multiple diseases. Drug discovery has traditionally focused on classical enzyme pockets, and chemical libraries are screened to identify inhibitors using biochemical and biophysical assays. Protein-protein interactions are notoriously difficult to target by this approach, since the interfaces frequently comprise large contact surfaces, which generally lack the deep pockets required for traditional medicinal chemistry approaches. In recent years, alternative strategies have emerged including fragment-based approaches to explore the chemical space or the use of peptide-based recognition molecules, such as hydrocarbon-stapled peptides, alpha mimetics, non-antibody protein scaffolds and antibody-aided technologies (reviewed in (1)).
Proteomimetic molecules have inherently greater potential to bind to critical interaction interfaces and sterically block protein-protein interactions. Traditional computational-based design tools have tended to focus on orthosteric inhibitors that directly target the interaction site, such as the receptor ligand-binding domain or active site of an enzyme. Novel approaches for therapeutic development include stabilization of protein complexes and identification of allosteric modulators that bind at sites distant to the interacting proteins (2, 3).
Currently, antibodies are the best-studied group of protein-based inhibitors with a wide range of therapeutic humanized monoclonal antibodies already in clinical use (4) . However, antibodies are not always ideal as molecular tools due to their multiple domains and chains, poor stability, high production costs and batch-to-batch variation, some of which may be due to glycosylation heterogeneity (5) . Artificial binding reagents (protein, RNA and DNA aptamers) are relatively small and make attractive alternatives to antibodies. We have recently established a scaffold consensus protein based on plant cystatins, called "Affimer", also known as "Adhiron" (12 kDa), which provides a highly stable scaffold (melting temperature = 101°C) for presenting one to three variable amino acid sequence regions for molecular recognition (6) . These variable regions (VRs) form a binding interface analogous to that presented by the complementarity-determining regions of an antibody. Affimer proteins are selected from phage display libraries (>3x10 10 ) allowing rapid identification of highly specific reagents that selectively bind to a target and often act as competitive or allosteric inhibitors (7) (8) (9) . Non-antibody binding proteins tend to recognize binding 'hot spots', which are small groups of amino acids on the target protein that contribute the majority of the interaction free energy (10) . We propose that Affimer proteins can be used to study protein function and to disrupt protein-ligand interactions. This unbiased approach may also increase the potential for introducing selectivity where multiple receptors bind to a single ligand, or conversely where multiple ligands bind to a single receptor. We have explored the potential utility of this approach using human Fcg Receptors (FcgRs) as a model system.
Human FcgR-ligand interactions constitute a biological system whereby multiple layers of complexity facilitate the fine-tuning of immune responses to infections. Immunoglobulin G (IgG) is the major ligand and mediates both pro-and anti-inflammatory effects following immune complex formation and engagement with different FcgRs. These activating and inhibitory receptors play a central role in the initiation and regulation of many immunological processes, including setting thresholds for B cell activation, recruitment of leukocytes, proinflammatory mediator release, phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) (11, 12) . Our genetic studies have demonstrated a number of independent associations with genes in the FCGR locus in different autoimmune and inflammatory diseases (13) (14) (15) . We have also described higher levels of FcgRIIIa on circulating CD14 ++ monocytes in rheumatoid arthritis patients compared with healthy controls, which was correlated with increased TNF release on exposure to immune complexes and inferior treatment outcomes (16) . Animal models also provide a strong rationale for targeting FcgRs in autoantibody-mediated inflammatory diseases, including autoantibody/immune complexinduced arthritis (17, 18) .
There are six functional human FcgRs subdivided into three classes (FcgRI, FcgRIIa, FcgRIIb, FcgRIIc, FcgRIIIa and FcgRIIIb). Multiple segmental duplications and deletions during hominid evolution have resulted in a family of highly homologous receptors with significant divergence of biological functions from those observed in rodents (19, 20) . The level of homology has been a major obstacle for the development of FcgR-specific therapeutics.
A number of FcgR class-specific monoclonal antibodies have been tested in humans, predominantly to block ADCC in immune thrombocytopenia purpura (ITP) (21) . An antibody against FcgRIII (CD16-3G8) led to transient increases in platelet count, demonstrating early efficacy. However, in addition to immunogenicity, a number of infusion and atypical hypersensitivity reactions were observed in conjunction with neutrophil and monocyte cytopenias that led to early termination of this program. Although these were believed to be secondary to unwanted engagement of the therapeutic Fc region with FcgRs, these were not abrogated when a humanised anti-FcgR with an aglycosylated Fc was used, suggesting alternative approaches may be required (reviewed in (22) ). Blockade of the critical proximal signalling molecule spleen tyrosine kinase (SYK) downstream of several FcgRs initially showed promising efficacy in rheumatoid arthritis (23) , chronic lymphocytic leukemia and non-Hodgkin's lymphoma (24) , providing clinical support for therapeutic FcgR blockade in human disease. However, further development in rheumatoid arthritis has been suspended, principally due to adverse off-target events (25) .
In this proof of principle study, we have screened artificial binding protein libraries against a recombinant, glycosylase-treated FcgRIIIa ectodomain and identified several FcgRIIIaspecific Affimer proteins. We present two Affimer proteins and their structures derived from X-ray crystallography of their complexes with FcgRIIIa, allowing structures to be solved at atomic resolution. Molecular dynamics (MD) simulations based on the X-ray crystallographic models supported the molecular basis of Affimer protein's mode of action and selectivity for FcgRIIIa. One AffimerAffimer protein [Protein Data Bank (PDB) ID code 5ML9) bound close to the Fc-binding domain acting as a steric inhibitor, whereas the other (PDB ID code 5MN2) recognized an allosteric site and bound in the interdomain hinge region.
Our results demonstrate the feasibility of generating highly-specific inhibitors of proteinligand interactions that bind unexplored sites and illustrate the utility of Affimer proteins in the study of protein function at both a molecular and cellular level.
Results

Identification and characterization of Fc RIIIa-specific Affimer proteins.
The extent of the challenge faced when developing specific agents against FcgRIIIa is illustrated by the structural alignment of FcgR crystal structures, demonstrating the high degree of target homology (Fig. 1a) . This is particularly true for FcgRIIIa and FcgRIIIb; only two amino acids are consistently different between FcgRIIIa and both common human neutrophil alloantigen types (NA1 and NA2, highlighted in red Fig. 1b) of FcgRIIIb, where there are a further four polymorphic amino acids in FcgRIIIb (highlighted in yellow in Fif. 1B):
NA2 has one morel site for N-linked glycosylation than FcgRIIIa (Asn64) and differs in having serine at residue 18, whereas FcgRIIIa and FcgRIIIb-NA1 have arginine at this locus.
For phage display we used FcgRIIIa ectodomain bait that had been produced in HEK293T cells in the presence of kifunensine and treated with endoglycosidase F1 to facilitate crystallization and to allow valid comparisons between structural and biophysical data. A total of 72 randomly chosen Affimer proteins were tested for binding to FcgRIIIa using phage ELISA after three rounds of selection. Of these 52 gave positive results, and DNA sequencing revealed six unique clones. The most frequently recovered Affimer proteins were expressed as soluble proteins. AfG3 differed from AfF4 in terms of primary sequence, being derived from different libraries; AfF4 has an extra VR on an N-terminal extension (NTE) (Fig.   1c) . We measured the FcgRIIIa-AfF4 and -AfG3 interactions by isothermal titration calorimetry (ITC), fitting a 1:1 binding model which gave estimated the Kds to be 217nM and 2.6µM respectively (Fig. 1d) . These ITC measurements may represent underestimates of Kd, as the N-values of 0.6 and 0.8 for AfF4 and AfG3, respectively, may indicate the presence of an inactive proportion of the analyte.
When amine coupled to carboxymethylated dextran sensor chips, the soluble ectodomain of FcgRIIIa interacted with both AfF4 and AfG3 with rapid association and dissociation rates ( KDs 963 nM for AfF4 and 253 nM for AfG3. Since kinetic measurements at high analyte concentrations were around the detection limits of the instrument used, we calculated steady state affinity from the same interactions, estimating the KDs to be 1.03µM for AfF4 and 2.77µM for AfG3. In addition we performed surface plasmon resonance (SPR) assays on fully glycosylated and endoglycosidase F1-treated FcgRIIIa immobilised via a biotinylated Cterminal Avitag on streptavidin-coated chips. The orientated receptor displayed higher steady-state affinity for AfF4 and AfG3 at ~860 and ~680nM, respectively, with negligible difference conferred by glycosylation (Fig S1b) . (Fig. 2a and b) . Our cellular assays on FcgR specificity demonstrated that AfF4 and AfG3 had only a marginal nonsignificant effect on the binding of HAG to ectopicallyexpressed FcgRIIa and FcgRIIIb, confirming considerably weaker interactions between the Affimer proteins and these homologous FcgRs (Fig. 2a) .
Importantly for therapeutic applications, AfF4 and AfG3 inhibited HAG binding to both the FcgRIIIa-158F and -158V allotypes. These Affimer proteins also displaced bound HAG from FcgRIIIa-158V; the allotype with a greater affinity for IgG1 complexes (Fig. 2c) .
To understand how the Affimer proteins blocked FcgRIIIa function and achieved such high specificity, we determined the crystal structures of AfF4 and AfG3 in complex with the FcgRIIIa ectodomain. The crystals belonged to space groups P212121 (AfF4) and P21 (AfG3), both diffracting to a resolution of 2.35 Å and were refined to convergence (Rwork/Rfree of 21.9/27.2% and 20.6/24.6%, respectively)( Table 1 ). All structures demonstrated that the core AffimerAffimer protein scaffold maintained its compact structure while the variable regions formed contacts with FcgRIIIa (rmsd < 0.5 Å in all cases). For clarity of referencing amino acid positions in FcgRs and Affimer proteins, FcgRIIIa and FcgRIIIb will be referred to as "ga-" and "gb-" whereas Affimer proteins will be referred to as "AfG3-" and "AfF4-", respectively. The two selected Affimer proteins bound to opposite faces of the FcgRIIIa ectodomain with AfF4 interfacing with the two FcgRIIIa-discriminating residues ga-Gly129 and ga-Tyr140, and AfG3 making contacts with FcgRIIIa extracellular domains 1 and 2.
The FcgRIIIa residues contributing to IgG binding, described in Ferrara et al. (27) Table S1 .
The overlapping buried surface area between IgG Fc and AfF4 totalled about half of the individual interfaces, suggesting that AfF4 probably acts as a competitive inhibitor of IgG
The AfF4-FcgRIIIa crystal structure shows that the AfF4 binding region includes two amino acids which discriminate between FcgRIIIa and FcgRIIIb -ga-Gly129/gb-Asp129 and gaTyr140/gb-His140 (Fig. 3a) . To provide atomistic insight into the preference of AfF4 for FcgRIIIa, we used MD simulations to compare the interactions of AfF4 with both Fc RIIIa and Fc RIIIb, by mutating the AfF4-FcgRIIIa complex in silico to resemble AfF4-FcgRIIIb-NA2.
Simulations were performed in triplicate for 200ns for each complex. Calculations of the rmsd ( Fig. S3) showed that triplicates remained stable during the timescale of the simulations, and that 200ns was sufficient for the RMSD to converge to a stable value, which
indicates that no significant global conformational changes took place.
Simulations were first subjected to atomic fluctuation analysis ( Fig. S4) , a measure of the average per-residue mobility throughout the simulations, which identified that VR2 of AfF4 was more mobile. Visual inspection of simulations around the AfF4 VR2-Fc RIIIa interface confirmed mobility of VR2 and that the aromatic ring of a-Y132 orientates towards aGly129 in Fc RIIIa simulations and away from b-Asp129 in Fc RIIIb NA2 simulations ( Fig.   3b and c) . This is likely due to steric clash of the tyrosine ring with the b-Asp129 side chain, causing the ring to move position. In MD simulations, the absence of a sidechain in aGly129 allows the AfF4-Phe57 (VR1) sidechain to sit on top of a-Gly129. AfF4-Phe57 in this position may also contribute to a hydrophobic pocket centred on AfF4 VR2 and a-Tyr132.
Conversely, the presence of a sidechain in b-Asp129 leads to steric clash with the AfF4-Phe57 sidechain. AfF4-Phe57 is therefore more mobile in Fc RIIIb-containing simulations (Fig 3b) , which may further weaken the AfF4 VR2-a-Tyr132 binding pocket. In summary, Narrowing of the inter-domain angle likely allows a-Trp99 to move closer to AfG3, leading to intercalation of a-Trp99 between VR1 and VR2 and the formation of several intermolecular H-bonds and an additional intra-molecular H-bond (Fig 4b, S5) . Conversely, as b-Ser18 in
Fc RIIIb forms only a single weak inter-domain contact, the inter-domain angle does not narrow and b-Trp99 is unable to form these contacts.
Measurement of the D1-D2 inter-domain angles (described by alpha carbon [Ca] atoms in ga-Gln83, -Trp90 and -Asn169) in unbound FcgRIIIb (1FNL), IgG-FcgRIIIa (3SGJ), and AfG3-FcgRIIIa (5MN2) identified hinge angles of 46°, 53° and 41°, respectively ( Fig. 4c and d) .
To analyse how this change in the angle may affect IgG binding, we superimposed the D2 domains (ga-Trp90-Gln174) derived from our x-ray structure 5MN2 on the FcgRIIIa structure bound to IgG (3SGJ). This shows that the overall shape of IgG-binding site is not disturbed and that only D2 is involved in binding. However, very subtle small conformational changes and a-Trp99 into close proximity.
Our proposed mechanism of IgG blocking is thus allosteric restraint of the interdomain angle that typically opens to accommodate IgG-binding (28) .
Affimer proteins block downstream effector functions in Fc RIIIa-expressing monocytic cells
We sought to demonstrate that AfF4 and AfG3 could block clinically relevant FcgRIIIa effector functions using the THP-1 monocytic cell line. We characterized the cell line and (Fig. 5a) . The marked increase in FcgRIIIa expression following culture with PMA allowed us to test the ability of the Affimer proteins to inhibit effector functions in the presence or absence of FcgRIIIa expression.
The contribution of FcgRIIIa to HAG-induced TNF production was determined in both resting and PMA-differentiated THP-1 by assessing the level of inhibition obtained with FcgRIIIspecific F(ab')2 fragments (Fig. 5b) . Our results showed that FcgRIIIa blockade with F(ab')2 fragments resulted in a 34.5% increase in cells showing no TNF production following differentiation with PMA and no demonstrable inhibition in TNF production in resting THP-1 cells that do not express appreciable amounts of FcgRIIIa (Fig. 5b) . We then assessed the ability of AfF4 and AfG3 to inhibit HAG-mediated TNF production. Resting THP-1 and PMAdifferentiated THP-1 cells were pre-treated with the Affimer proteins and assessed for their ability to produce TNF in response to HAG. Each AffimerAffimer protein demonstrated inhibition of TNF production in PMA-differentiated THP-1 at a level comparable to that observed with the FcgRIIIa-specific F(ab')2 fragment. Resting THP-1 that do not express FcgRIIIa display less than 10% inhibition of HAG-induced TNF production, consistent with the levels seen following blockade with the FcgRIIIa-specific F(ab')2 fragment.
We then compared the ability of Affimer proteins to inhibit phagocytosis of IgG-opsonized Escherichia coli in both resting and PMA-differentiated THP-1 cells and compared this with the level of inhibition observed following pre-treatment with FcgRIII-specific F(ab')2. Inhibition of phagocytosis by each of the Affimer proteins was only observed in PMA-differentiated THP-1 where FcgRIIIa was expressed, and at a comparable level to cells treated with FcgRIII F(ab')2, consistent with data on inhibition of TNF production (Fig. 5c) .
Discussion
We describe the isolation of highly specific steric and allosteric inhibitors of FcgRIIIa using 
Supplementary Information Methods
All reagents were purchased from Sigma-Aldrich (Dorset, UK) unless stated otherwise.
Fc R Cloning Strategy
FcgR ectodomains (FcgRIIIa 158F, FcgRIIa 131H) were amplified by PCR (see Table S4 for primer sequences) and cloned into pOPINTTG (OPPF) using the InFusion system (Clontech Laboratories Inc.) (32, 33) .
Alternative allotypes (FcgRIIIa-158V, FcgRIIa-131R) were produced using QuikChange Table S4 for details of primers used).
These sequences were cloned into a plasmid encoding the enzymatic SNAP tag (New England Biolabs) derived from pFB HYG (a gift from Dr. J.E. Burns). The plasmids were used to transfect Phoenix A packaging cells (Nolan labso that replication-defective virus particles were produced in the supernatant. These supernatants were filtered and used to infect HEK293 cells (in the case of FcgRIIIa-expressing cells, virus particles were used to infect cells which had already been infected with a neo resistance vector for stable expression of the common g-chain of FceRI gene (FCER1G, NM_004106.1). This double transfection was carried out to allow cell surface expression of FcgRIIIa which is dependent on the common g-chain of FceRI). Primer sequences for the common g-chain of FceRI are shown in Table S4 . After 10 days of antibiotic selection, the cells were tested for surface expression using FITC-labelled anti-CD16 mouse monoclonal DJ130c (Dako) which recognises an epitope in the first extracellular domain. This antibody was also used to show expression of FcgRIIIb. Expression of ectopically-expressed FcgRIIa was tested using mouse monoclonal AT10 (CD3204, Caltag-Medsystems).
Protein production and purification
Proteins were secreted from HEK293T adherent cells in roller bottles. Purification was by immobilized metal affinity chromatography followed by gel filtration chromatography using a liquid substrate (Seramun Diagnostica GmBH) and absorbance measured at 560 nm.
Positive binders were submitted for DNA sequence analysis (Beckman Coulter Genomics).
c. Recloning and modifications
The coding sequences of selected Affimer proteins were PCR amplified, restriction digested with NheI and PstI and cloned into pET11a containing the Affimer proteins scaffold coding region. For biotin labelling Affimer proteins were cloned into a pET11a-scaffold construct encoding a C-terminal cysteine. Individual clones were sequenced to confirm the presence of the correct insert. Plasmids were transformed into BL21 (DE3) cells and cultures grown in 400ml of LB medium to an OD600 of 0.6 at 37°C, before addition of isopropyl -D-1-thiogalactopyranoside to 1mM. After a further 6hr, cells were harvested, resuspended in 25ml of 1x Bugbuster (Novagen,) with benzonase, mixed for 20min, then heated to 50°C for 20min. The cleared supernatant was mixed with 500µl Ni-NTA resin (Expedeon) for 1hr, washed 3 times in 30ml wash buffer (50mM phosphate buffered saline (PBS), 500mM NaCl, 20mM imidazole, pH 7.4) and eluted in 1ml of elution buffer (50mM PBS, 500mM NaCl, 300mM imidazole, pH 7.4).
d. Confirmation of FcgRIIIa binding
Freshly purified Affimer proteins were used in surface plasmon resonance (SPR) assays to confirm binding to both common FcgRIIIa allotypes (158F and V). SPR was carried out on a BIAcore T200 biosensor (GE Healthcare). Soluble FcgRIIIa ectodomains of the 158V allotype were immobilised (100RU) in 10mM acetate pH5.0 on a CM5 sensor chip (GE Healthcare) using amine coupling, as directed by the manufacturer. Affimer proteins were used as analytes in single cycle kinetics with 2min injections of increasing concentrations from 123nM through to 10µM at a flow rate of 30µl/min in HBS-EP+ running buffer. The
FcgRIIIa surface was regenerated between cycles using a 60s injection of 10mM glycine pH2.0 at 30µl/min.
A blank amine coupled flow cell was used as reference and zero concentration controls were used in double-referencing. All analysis was carried out using the BIAcore T200 Evaluation Software v1.0. Langmuir 1:1 kinetic models were fitted to reference-subtracted sensorgrams and steady state affinity models were fitted.
For isothermal titration calorimetry (ITC), protein samples were dialysed against PBS overnight at 4°C and this buffer was used for control titrations. ITC was performed using an iTC200 instrument (Microcal, Malvern Instruments) at 25°C. An initial injection of 0.5µl over Table   S3 .
Crystals were detected in a number of conditions with data being collected from condition 41 For diffraction data collection, crystals were loop mounted and cryo-cooled in liquid nitrogen.
Data were collected at Beamline I24, Diamond Light Source, with the X-ray beam defocused to 20×20 m 2 from multiple positions on each crystal. All diffraction data were integrated using XDS(41) and scaled using AIMLESS (42) . Phases were obtained via molecular replacement using PHASER (43) . A subsection of a complex of an Affimer protein bound to a soluble protein was used as a search model. Refinement was carried out using PHENIX (44) .
Ligands and sugar modifications were built manually into Fo-Fc maps using COOT (45) . In the case for AdG3 additional noncrystallographic symmetry torsion restraints were applied during refinement. The quality of the protein structure was assessed using MOLPROBITY.
Data collection and refinement statistics are given in Table 1 .
The residues involved in Affimer protein binding to FcgRIIIa were identified based on the Protein Interaction Calculator(46) and visual inspection.
Molecular dynamics simulations.
Molecular dynamics (MD) simulations were prepared with the AmberTools 14 suite of programs and performed with AMBER14 (47), ff14SB47 (48) and GLYCAM_06j-1 (49).
Simulations used 128 processors of the MARC1 supercomputer available at Leeds. To simulate Affimer protein-FcgR interactions in water, models were first generated of each
Affimer protein in complex with either FcgRIIIa (-158F allotype for AdG3 and -158V allotype for AdF4) or FcgRIIIb-NA2. The FcgRIIIb-containing complex was generated by mutation of the FcgRIIIa-Affimer protein crystal structures to resemble the FcgRIIIb-NA2 through the use of TRITON/MODELLER (50).
After mutagenesis, the xleap program of AmberTools 14 was used to add hydrogen atoms, form disulphide bridges and add 1,4 linked D-N-acetyl glucosamine (GlcNAc) residues at glycosylation sites in FcgRIIIa/FcgRIIIb. Complexes were then placed in a TIP3P water box with a 10.0-Å cut-off, and the system was neutralized with Na+ ions. The system was equilibrated through an initial energy minimization, which was followed by 80ps of restrained molecular dynamics during which the system was heated to 300K with gradual releasing of
restraints. An unrestrained MD simulation of 200ns was then performed. For each complex, simulations were repeated in triplicate.
Calculations of the Root Mean Square Deviation (RMSD) showed that all simulations remained stable, and that 200ns was sufficient for the RMSD to converge to a stable value, which indicates that no significant global conformational changes are taking place over MD timescales.
Desolvated trajectories were analysed with the cpptraj module of AMBER14, which was used to calculate inter-and intra-molecular H-bonds, per residue atomic fluctuations and inter-atomic distances. H-bonds with a cutoff of 3.2-Å and 160°, which were present for 
